<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" style="width: 100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a1" bgcolor="#cccccc" valign="top" width="10%" align="left"&gt;Center&lt;/th&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" width="25%" align="left"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" width="25%" align="left"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" width="40%" align="left"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="10%" headers="a1"&gt;OC&lt;/td&gt;&lt;td valign="top" width="25%" headers="a2"&gt;June 24, 2013&lt;/td&gt;&lt;td valign="top" width="25%" headers="a3"&gt;1:00 p.m. - 3:00 p.m.&lt;/td&gt;&lt;td valign="top" width="40%" headers="a4"&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Ave.&lt;br /&gt;Bldg. 31, Rm. 1503, Section A &lt;br /&gt;Silver Spring, MD 20993-0002&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;This meeting will be held via teleconference (301-796-4100 or 866-901-3913 passcode: 665127) and via adobe connect (&lt;a href="https://collaboration.fda.gov/scienceboard"&gt;https://collaboration.fda.gov/scienceboard&lt;/a&gt;). Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at &lt;a target="" href="[!--$wcmUrl('link','UCM241740')--]"&gt;Public Meetings at the FDA White Oak Campus&lt;/a&gt;.&amp;nbsp;Please note that visitors to the White Oak Campus must enter through Building 1.&lt;/p&gt;&lt;h4&gt;Agenda&lt;/h4&gt;&lt;p&gt;The Science Board will be provided with a revised draft final report from the Center for Devices and Radiological Health (CDRH) Research Review subcommittee.&amp;nbsp; The revised framework regarding the upcoming subcommittee to evaluate the Agency&amp;rsquo;s continuing work to address the challenges identified in Science Board&amp;rsquo;s 2007 &amp;quot;Science and Mission at Risk&amp;quot; Report will be discussed.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;FDA intends to make the complete set of background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, all efforts will be made to try and provide the background material at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;strong&gt;Background material&lt;/strong&gt; &lt;ul&gt;&lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM337593')--]"&gt;2013 Meeting Materials, Science Board to the FDA&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h4&gt;&lt;strong&gt;Public Participation &lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul type="disc"&gt;&lt;li&gt;Written submissions may be made to the contact person on or before Monday, June 17, 2013&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between 1:15 p.m. and 1:45 p.m. on June 24, 2013. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before Friday, June 7, 2013&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by Monday, June 10, 2013.&lt;/p&gt;&lt;h4&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h4&gt;&lt;p&gt;Martha Monser&lt;br /&gt;Office of Chief Scientist&lt;br /&gt;Office of the Commissioner&lt;br /&gt;Food and Drug Administration&lt;br /&gt;White Oak Bldg 32, Room 4286&lt;br /&gt;10903 New Hampshire Ave.&lt;br /&gt;Silver Spring, Maryland 20993&lt;br /&gt;Phone: 301&amp;ndash;796-4627&lt;br /&gt;Fax: 301-847-8617&lt;br /&gt;E-mail: &lt;a href="mailto:martha.monser@fda.hhs.gov"&gt;martha.monser@fda.hhs.gov&lt;/a&gt;&lt;/p&gt;&lt;p&gt;A notice in the &lt;em&gt;Federal Register&lt;/em&gt; about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.&amp;nbsp; Therefore, you should always check the Agency&amp;rsquo;s Web site at &lt;a href="http://www.fda.gov/AdvisoryCommittees/default.htm"&gt;http://www.fda.gov/AdvisoryCommittees/default.htm&lt;/a&gt; and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;ul type="disc"&gt;&lt;li&gt;FDA Advisory Committee Information Line 1-800-741-8138 &lt;br /&gt;(301-443-0572 in the Washington DC area) and follow the prompts to the desired center or product area.&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Martha Monser at (301) 796-4627 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;procedures on public conduct during advisory committee meetings&lt;/a&gt;.&amp;nbsp;&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
